1. Ocular Behçet Disease—Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset
- Author
-
Michael Ostrovsky, Amir Rosenblatt, Salam Iriqat, Abdallah Shteiwi, Yael Sharon, Michal Kramer, Vicktoria Vishnevskia-Dai, Shaul Sar, Yosif Boulos, Oren Tomkins-Netzer, Natalie Lavee, Yael Ben-Arie-Weintrob, Hadas Pizem, Tamar Hareuveni-Blum, Marina Schneck, Raz Gepstein, Dua Masarwa, Nakhoul Nakhoul, Erez Bakshi, Shiri Shulman, Michaella Goldstein, Dan Ramon, Marina Anouk, and Zohar Habot-Wilner
- Subjects
Behçet disease ,ocular Behçet disease ,juvenile-onset Behçet disease ,adult-onset Behçet disease ,late-onset Behçet disease ,Behçet uveitis ,Biology (General) ,QH301-705.5 - Abstract
Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (n = 25, 14.3%), adult-onset (n = 120, 68.6%) and late-onset (n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar.
- Published
- 2023
- Full Text
- View/download PDF